Transcatheter aortic valve implantation (TAVI) with the Evolut system (Medtronic) is as successful as surgical valve replacement in low-risk aortic stenosis patients. Data from the Evolut low risk trial were presented at the American College of Cardiology 68th Annual Scientific Session (ACC 19) and published simultaneously in the New England Journal of Medicine. It compared the minimally invasive Evolut transcatheter aortic valve implantation (TAVI) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients.

The Evolut Low Risk trial was a global, prospective, multicentre, randomised trial that evaluated three valve generations (CoreValve, Evolut R and Evolut PRO valves) across a variety of valve sizes in >1,400 low-risk severe aortic stenosis patients deemed to have a low mortality risk with surgery with a predicted risk of mortality of <3%. It met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3% vs. 6.7% posterior probability of non-inferiority >0.999). Additionally, the prespecified 30-day safety composite of all-cause mortality, disabling stroke, life-threatening bleeding, major vascular complications or acute kidney injury was significantly lower for valve implantation compared to open heart surgery (5.3% vs. 10.7%), as was the rate of the composite endpoint of all-cause mortality or disabling stroke at 30 days (0.8% vs. 2.6%). The pacemaker rate was greater in the transcatheter implantation treatment arm.

Transcatheter implantation also demonstrated excellent haemodynamic (blood flow) performance, with significantly lower mean aortic valve gradients (8.6mmHg vs. 11.2mmHg) and larger effective orifice areas than surgery (2.3 vs. 2.0) at 12 months. The implantation treatment arm also showed statistically lower rates of heart failure hospitalisations (3.2% vs. 6.5%) and disabling stroke (0.8% vs. 2.4%) compared to surgery at 12 months.

Michael Reardon (Houston Methodist DeBakey Heart and Vascular Center), principal investigator and senior author of the trial, says: “Low-risk aortic stenosis patients have unique characteristics due to their tendency to be younger and more active than their higher-risk counterparts. These data suggest that not only did TAVI match the gold standard of surgery, but it demonstrated statistical superiority across several key endpoints, including quality of life and haemodynamics—important considerations for severe aortic stenosis patients who may be more active.”

Source CarrdiovascularNews

Duc Tin Clinic

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
TOP